3-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]propanal

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-[2-(2-Aminoethoxy)ethoxy]ethoxy]propanal
• 英文别名: 3-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]propanal
• 化学式: C₉H₁₉NO₄
• 分子量: 205.25
• InChiKey: PGRFVPHGKLDGEE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  14
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• EGF(A) analogues with fatty acid substituents
  申请人：Novo Nordisk A/S

  公开号：US10822385B2

  公开（公告）日：2020-11-03

  The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.

  本发明涉及源自 LDL-R 的 EGF(A) 结构域的化合物，特别是包含野生型 EGF(A) (LDL-R(293-332))序列的多肽类似物和至少一个包含至少一个脂肪酸基团的取代基的化合物。本发明还涉及其药物组合物和药物用途。本发明的新型 EGF(A) 化合物可用于降低胆固醇、血脂异常和心血管疾病等领域的治疗。
• Bifunctional compounds
  申请人：Novo Nordisk A/S

  公开号：US11130794B2

  公开（公告）日：2021-09-28

  The application discloses compounds useful in treatment of diabetes, weight loss and/or reduction of cardiovascular risks. The compounds are bi-functional and therefore suitable as a simple treatment for patients that may benefit from treatment with both a GLP-1 receptor agonist and a PCSK9 inhibitor.

  该申请公开了可用于治疗糖尿病、减肥和/或降低心血管风险的化合物。这些化合物具有双功能，因此适合作为一种简单的治疗方法，用于治疗可能同时从 GLP-1 受体激动剂和 PCSK9 抑制剂治疗中获益的患者。
• EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS
  申请人：Novo Nordisk A/S

  公开号：US20190016768A1

  公开（公告）日：2019-01-17

  The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
• EGF(A) ANALOGUES, PREPARATION, FORMULATIONS AND USES THEREOF
  申请人：Novo Nordisk A/S

  公开号：US20200165313A1

  公开（公告）日：2020-05-28

  The invention relates to compounds derived from the EGF(A) domain of LDL-R, in particular compounds comprising a peptide analogue of the wild-type EGF(A) (LDL-R(293-332)) sequence and at least one substituent comprising at least one fatty acid group. The invention also relates to a pharmaceutical composition thereof and use a medicament. The novel EGF(A) compounds of the invention are useful as treatment e.g. in the field of cholesterol lowering, dyslipidaemia and cardiovascular disease.
• CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY
  申请人：Novo Nordisk A/S

  公开号：US20220125940A1

  公开（公告）日：2022-04-28

  Peptide co-agonists of the human GLP-1 and GIP receptors suitable for oral delivery, including long-acting derivatives, and their medical use in treatment and/or prevention of obesity, diabetes, and/or liver diseases are described.